| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA2297566
Max Phase: Preclinical
Molecular Formula: C25H30N2O4S
Molecular Weight: 454.59
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: CC(C)(S)C(=O)NC1(C(=O)NC(Cc2ccc(-c3ccccc3)cc2)C(=O)O)CCCC1
Standard InChI: InChI=1S/C25H30N2O4S/c1-24(2,32)22(30)27-25(14-6-7-15-25)23(31)26-20(21(28)29)16-17-10-12-19(13-11-17)18-8-4-3-5-9-18/h3-5,8-13,20,32H,6-7,14-16H2,1-2H3,(H,26,31)(H,27,30)(H,28,29)
Standard InChI Key: PJLGFANHDUKQKS-UHFFFAOYSA-N
Associated Targets(Human)
Endothelin-converting enzyme 1 674 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 454.59 | Molecular Weight (Monoisotopic): 454.1926 | AlogP: 3.60 | #Rotatable Bonds: 8 |
| Polar Surface Area: 95.50 | Molecular Species: ACID | HBA: 4 | HBD: 4 |
| #RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 4.08 | CX Basic pKa: | CX LogP: 4.25 | CX LogD: 1.13 |
| Aromatic Rings: 2 | Heavy Atoms: 32 | QED Weighted: 0.46 | Np Likeness Score: -0.26 |
References
| 1. Tanneeru K, Sahu I, Guruprasad L. (2013) Ligand-based drug design for human endothelin converting enzyme-1 inhibitors, 22 (9): [10.1007/s00044-012-0433-z] |
Source
Source(1):